Brisbane, Australia, 26 February 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provides an update on its two-year, non-exclusive software licencing agreement with workplace healthcare solutions provider, Workplace Medicine Australia Ltd (“WMA”).
As per the ASX announcement made on 19 November 2020, WMA will integrate ResApp’s acute respiratory test ResAppDx, into its holistic workplace health and wellbeing management platform Medetective, which was expected to launch in February 2021.
Following consultations with potential partners and medical practices, WMA has decided to considerably broaden its proposed business plan to create an expanded ecosystem for patients, clinicians and corporate partners. As such, the launch date has been moved to Q4 CY2021.
WMA has reaffirmed their commitment to ResApp that its technology is integral to the expanded Medetective offering and the company looks forward to working with WMA to facilitate a successful launch.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.